Since its launch in 2015 the ESMO-MCBS has been presented on a number of occasions
Webcasts and presentations from ESMO Congresses can be accessed by ESMO members, through OncologyPRO.org and conference attendees, through the ESMO conference platform using their LAST NAME and ESMO ID to login (the number printed on your congress badge).
ESMO Virtual Congress 2020: September and October 2020
The scale was presented or referenced during the following sessions at the ESMO Virtual Congress 2020
Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO-MCBS
Thursday, 17 September: E-Poster Display Session
Challenges in the development and real-world use of the ESMO-MCBS
Sunday, 20 September: Special Session, 11:15 - 12:15 (Channel 2)
Chair: E. De Vries (Groningen, Netherlands)
ESMO-MCBS: What is new and how are we expanding
Nathan Cherny (Jerusalem, Israel)
How can the ESMO-MCBS contribute to a higher QoL for patients?
Andrew Bottomley (Brussels, Belgium)
Prioritising cancer systemic therapies using the ESMO-MCBS: The Israeli experience
Raya Leibowitz (Tel Aviv, Israel)
Shortcomings in study design: Implementation that can skew the ESMO-MCBS results
Bishal Gyawali (Kingston, Canada)
Q&A and live discussion
All Speakers online Chairs to moderate Q&A
Connecting the dots: The ESMO vision on the value of cancer medicines
Monday, 21 September 2020; Educational Session, 11:15 - 12:15 (Channel 1)
Chair: Josep Tabernero (Barcelona, Spain)
Where everything started: The ESMO MCBS
E.G. Elisabeth De Vries (Groningen, Netherlands)
Where it was logical to go: The ESMO economic model for cancer medicines
Panagiotis Kanavos (London, United Kindgom)
What we need to bring into the equation: The ESMO ESCAT
Joaquin Mateo (Barcelona, Spain)
Q&A and live discussion
Josep Tabernero (Barcelona, Spain)
Proffered Paper - Public Policy
Monday, 21 September 2020; 14:25 - 16:05 (Channel 1)
1583O - Clinical benefit of cancer drugs approved in Switzerland during the last decade
The scale was presented or referenced during the following sessions at the ESMO Congress 2019
ESMO-MCBS: What have we learnt and how can we expand?
Saturday, 28 September: Special Session, 14:45-16:15, Salamanca Auditorium (Hall 3)
Introduction
E. De Vries (Groningen, Netherlands)
Lessons learned from ESMO-MCBS testing of multiple adjuvant breast cancer trials
S. Paluch-Shimon (Jerusalem, Israel)
Lessons learned from ESMO-MCBS testing of multiple adjuvant colon cancer
D. De Groot (Groningen, Netherlands)
Taking toxicity into account in the curative setting
N. I. Cherny (Jerusalem, Israel)
Kazakhstan: A success story of working with WHO and ESMO towards sustainable cancer care
D. Kaidarova (Almaty, Kazakhstan), A. Ilbawi (Geneva, Switzerland)
Conclusions
E. De Vries (Groningen, Netherlands)
Poster Discussion Session - Public policy
Sunday, 29 September, 10:15 - 11:45, Leon Auditorium (Hall 3)
1631PD_PR - Clinical benefit and prices of cancer drugs in the US and Europe
Educational Session, Surviving a cancer diagnosis with a good QoL
Monday, 30 September, 08:30 - 10:00, Santander Auditorium (Hall 3)
The physician’s perspective
J. Nuver (Groningen, Netherlands)
EORTC’s work on survivorship
M. Pe (Brussels, Belgium)
Can value frameworks (such as ESMO-MCBS) contribute to a higher QoL?
A. Bottomley (Brussels, Belgium)
Employment and a cancer diagnosis: How does it work in practice?
I. Lebrocquy (Den Haag, Netherlands)
The patient’s perspective
R. Wilson (Church Stretton, United Kingdom)
Discussion
Proffered paper session - Public policy
Monday, 30 September, 16:30 - 18:00, Salamanca Auditorium (Hall 3)
1628O - Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia
The scale was presented or referenced during the following sessions at the ESMO Congress 2018
Special Session, ESMO-MCBS in perspective
Friday, 19 October, 14:00 - 15:30, ICM - Room 14c
Introduction
E. De Vries (Groningen, Netherlands)
Comparative assessment of clinical benefit using the ESMO-MCBS v1.1 and the ASCO Value Frameworks Net Health Benefit Score
N. I. Cherny (Jerusalem, Israel)
ESMO-MCBS v1.1 applied in haematological diseases
B. Kiesewetter-Wiederkehr (Vienna, Austria)
How to help countries priorities their cancer systemic therapies –report from the WHO
A. Ilbawi (Geneva, Switzerland)
Conclusions
E. De Vries (Groningen, Netherlands), N. I. Cherny (Jerusalem, Israel)
Poster Discussion Session - Public health policy
Saturday, 20 October, 09:15 - 10:30, Hall B4 - Room 19
1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)
1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval
1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs
1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores
Proffered paper session - Public health policy
Monday, 22 October, 14:45 - 16:15, Hall B3 - Room 22
The scale was presented or referenced during the following sessions at the ESMO Congress 2017:
Poster Discussion Session
Saturday, 9 September, 16:30-17:45, Tarragona Auditorium
Special Session, Cost value and assessment tools of therapies in modern oncology
Sunday, 10 September, 16:30 - 18:00, Alicante Auditorium
Introduction
N Cherny (Jerusalem, Israel)
Principles and reflections on cost, value and sustainability of anticancer therapies
I Tannock (Toronto, Canada)
ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS): New version 1.1
N Cherny (Jerusalem, Israel)
Integrating the ESMO-MCBS in ESMO Clinical Practice Guidelines
G Pentheroudakis (Ioannina, Greece)
Implementation of the ESMO-MCBS scale
Discussion and conclusions, led by
E de Vries (Groningen, Netherlands)
Proffered Paper Session
Monday, 11 September, 16:30 - 18:00, Alicante Auditorium
1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs.
1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS
1437O_PR - Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval
The scale was presented or referenced during the following sessions at the ESMO Congress 2016
Poster Display
Saturday, 8 October, 13:00-14:00, Hall E
Poster Discussion session
Saturday, 8 October, 16:30-17:30, room Helsinki
Special Session
Sunday, 9 October, 14:45-16:15, room Helsinki
Clinical benefit of Cancer Drugs
Special Symposium
Monday, 10 October, 11:00-12:30, room Helsinki
ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing in the magnitude of clinical benefit
Proffered Paper session
Monday, 10 October, 16:30-18:00, room Oslo
During an ESMO Asia 2015 Special Session, Resource constraints as a barrier to lung cancer management: Developing nations, C. Zielinski presented the ESMO Magnitude of Clinical Benefit Scale.
September 2015
Elisabeth de Vries presenting the ESMO Magnitude of Clinical Benefit Scale during the ESMO Society session at ECC 2015
The scale was presented at the ESMO Society Session (28 September) during the European Cancer Congress 2015 in Vienna, Austria. E.G. de Vries, Netherlands, presented the scale and A. Eniu, Romania explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.
Watch E. G. de Vries's presentation
Watch A. Eniu’s presentation
In addition, aspects of the ESMO-MCBS were highlighted and discussed during three further sessions at ECC 2015:
- ESO Society Session: ‘Is innovation Affordable?’, 26 September: The ESMO initiative on affordable drugs, Speaker: M. Piccart (Belgium)
- Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September: The Value of anticancer treatment, Speaker: E. G. de Vries (Netherlands)
- Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September: Chair: E.G. de Vries (Netherlands); Clinical Benefit scale: The European proposal, Speaker: M. Piccart (Belgium); Clinical Benefit scale: The challenge of fairness, Speaker: U. Dafni (Greece)
May 2015
ESMO-MCBS presented at the ESMO/ASCO Joint Session (30 May) during ASCO 2015, Chicago